Etizolam
NERVOUS SYSTEM
Also known as: AHR-3219, depas, Y 7131, Y-7131
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Etizolam is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1984. DrugCentral lists 4 molecular targets, including GABRA1|GABRG2|GABRB2, GABRG2|GABRB3|GABRA2 and GABRG2|GABRB3|GABRA3. Recorded indications include Anxiety.
- Molecular targets: GABRA1|GABRG2|GABRB2, GABRG2|GABRB3|GABRA2, GABRG2|GABRB3|GABRA3 and GABRG2|GABRB3|GABRA5 (4 listed in DrugCentral).
- Indications: Anxiety.
- ATC code: N05BA19 (Benzodiazepine derivatives).
- Molecular formula: C17H15ClN4S; molecular weight 342.85 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Anxiety
Mechanism & targets
Molecular targets (4)
| Target | Gene | Action | Activity |
|---|---|---|---|
| GABA-A receptor alpha-1/beta-2/gamma-2 | GABRA1|GABRG2|GABRB2 | unknown | EC50 8.10 |
| GABA-A receptor alpha-2/beta-3/gamma-2 | GABRG2|GABRB3|GABRA2 | unknown | — |
| GABA-A receptor alpha-3/beta-3/gamma-2 | GABRG2|GABRB3|GABRA3 | unknown | — |
| GABA-A receptor alpha-5/beta-3/gamma-2 | GABRG2|GABRB3|GABRA5 | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1984-01-01 | YEAR INTRODUCED | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N05BA19 | NERVOUS SYSTEM › PSYCHOLEPTICS › ANXIOLYTICS › Benzodiazepine derivatives |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Toxicity to various agents | 1453.7 |
| Drug abuse | 449.2 |
| Respiratory depression | 243.3 |
| Hepatic function abnormal | 195.8 |
| Overdose | 192.7 |
| Altered state of consciousness | 122.9 |
| Pulmonary oedema | 121.7 |
| Intentional overdose | 101.1 |
| Alcohol interaction | 96.0 |
| Interstitial lung disease | 93.8 |
| Counterfeit product administered | 84.8 |
| Fatigue | 83.1 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Etizolam is on its molecule page.
| Molecular formula | C17H15ClN4S |
|---|---|
| Molecular weight | 342.85 g/mol |
| CAS number | 40054-69-1 |
| InChIKey | VMZUTJCNQWMAGF-UHFFFAOYSA-N |
| PubChem CID | 3307 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Etizolam used for?
DrugCentral lists the following indications for Etizolam: Anxiety.
How does Etizolam work?
Its molecular targets in DrugCentral include GABRA1|GABRG2|GABRB2, GABRG2|GABRB3|GABRA2, GABRG2|GABRB3|GABRA3 and GABRG2|GABRB3|GABRA5.
When was Etizolam first approved?
Etizolam was first approved by the YEAR INTRODUCED in 1984.
What is the chemical formula of Etizolam?
Etizolam has the molecular formula C17H15ClN4S and a molecular weight of 342.85 g/mol.
Browse: all drugs starting with E · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1102 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1289779 — compound record and bioactivity
- PubChem CID 3307 — chemical identifiers
- DrugBank DB09166 — drug record
- FDA UNII A76XI0HL37 — substance identity
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.